chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pfizer-BioNTech COVID-19 Vaccine  17 hours post-vaccine: a brief moment of dizziness before waking and weakness upon waking but subsiding immediately.  Upon waking: left sided neck pain, and left sided chest pain aggravated only by extending left arm forward.   24 hours post-vaccine: fatigue and brain foggyness 30 hours post-vaccine: aforementioned joint pain relieves 48 hours post-vaccine: relief of most symptoms
Patient states arm so painful he could not life it. Had to go to the emergency room because it was the worst pain he has ever experienced in his life. Pt stated he had excruciating pain in his arm.
Information has been received from a company representatives daughter concerning a 16 year old female who on an unspecified date was vaccinated with a first dose of GARDASIL. Subsequently the patient's shot hurt. Subsequently, the patient recovered. On an unspecified date was vaccinated
Monovalent doses administered after the BUD to patient; no adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Monovalent doses administered after the BUD to patient) and NO ADVERSE EVENT (no adverse event) in an adolescent male patient who received mRNA-1273 (Spikevax) (batch no. 059H21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 22-Feb-2022, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Monovalent doses administered after the BUD to patient) and NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Monovalent doses administered after the BUD to patient) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Monovalent doses administered after the BUD to patient).    No concomitant medication information was provided. No treatment medications were provided
Expired vaccine used; Product administration error; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and PRODUCT ADMINISTRATION ERROR (Product administration error) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and PRODUCT ADMINISTRATION ERROR (Product administration error). On 15-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and PRODUCT ADMINISTRATION ERROR (Product administration error) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant Medications details were provided. No Treatment Medications details were provided.
Unable to lay on the injection site; Overall I am feeling awful; Whole body aches; All joint pain; Muscle ache; I am experiencing fever of 100; Nauseated; Bad headache; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE DISCOMFORT (Unable to lay on the injection site), FEELING ABNORMAL (Overall I am feeling awful), PAIN (Whole body aches), ARTHRALGIA (All joint pain) and MYALGIA (Muscle ache) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 626A21A and 040A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Mar-2021, the patient experienced VACCINATION SITE DISCOMFORT (Unable to lay on the injection site), FEELING ABNORMAL (Overall I am feeling awful), PAIN (Whole body aches), ARTHRALGIA (All joint pain), MYALGIA (Muscle ache), PYREXIA (I am experiencing fever of 100), NAUSEA (Nauseated) and HEADACHE (Bad headache). At the time of the report, VACCINATION SITE DISCOMFORT (Unable to lay on the injection site), FEELING ABNORMAL (Overall I am feeling awful), PAIN (Whole body aches), ARTHRALGIA (All joint pain), MYALGIA (Muscle ache), PYREXIA (I am experiencing fever of 100), NAUSEA (Nauseated) and HEADACHE (Bad headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 31-Mar-2021, Body temperature: 100 (High) 100 F.         Concomitant product use was not provided. Treatment information was not provided.   Action taken with mRNA-1273 in response to the events was  not applicable.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Drug ineffective; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 76-year-old male patient received BNT162b2 (BNT162B2), on 10Oct2022 as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: COVID-19 (medically significant) with onset Oct2022, outcome "unknown", described as "COVID 19 Treatment"; DRUG INEFFECTIVE (medically significant) with onset Oct2022, outcome "unknown". The patient underwent the following laboratory tests and procedures: Body temperature: 99, notes: 99 temp; SARS-CoV-2 test: Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical information: Anti-viral details: Product: COVID 19 Treatment Brand: Paxlovid. Treatment start date was14Oct2022 and treatment stop date was 18Oct2022. No other medication in 2 weeks and no allergies reported.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
FELT EXTREMELY LETHARGIC; SLIGHT AND MILD SHORTNESS OF BREATH; MUSCLE WEAKNESS AND WOBBLY LEG WHENEVER PATIENT TRIED TO GET UP CANNOT STAY UP FOR LONG (ALMOST FELL GETTING OFF THE TRUCK); CHILLS; EXTREME TENDERNESS IN THE ARM (INJECTION SITE); VOMITING; 101 DEGREE FAHRENHEIT BODY TEMPERATURE; DIZZINESS; CANNOT STAND UP; This spontaneous report received from a patient concerned a 61 year old male. The patient's height, and weight were not reported. The patient's past medical history included: asthma, and concurrent conditions included: non-smoker, and non-alcohol user, and other pre-existing medical conditions included: The patient had no known allergies. The patient did not have any drug abuse or illicit drug use. Patient had never been hospitalized, never broke a bone and never had an operation. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 203A21A, and 211A21A expiry: UNKNOWN) dose was not reported, administered on 30-SEP-2021 for prophylactic vaccination. No concomitant medications were reported. On 30-SEP-2021, the patient experienced dizziness. On 30-SEP-2021, the patient experienced cannot stand up. On 30-SEP-2021, the patient experienced slight and mild shortness of breath. On 30-SEP-2021, the patient experienced muscle weakness and wobbly leg whenever patient tried to get up cannot stay up for long (almost fell getting off the truck). On 30-SEP-2021, the patient experienced chills. On 30-SEP-2021, the patient experienced extreme tenderness in the arm (injection site). On 30-SEP-2021, the patient experienced vomiting. On 30-SEP-2021, the patient experienced 101 degree fahrenheit body temperature. Laboratory data included: Body temperature (NR: not provided) 101 F. On 07-OCT-2021, the patient experienced felt extremely lethargic. Laboratory data (dates unspecified) included: COVID-19 virus test (NR: not provided) Negative. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from 101 degree fahrenheit body temperature, dizziness, vomiting, chills, muscle weakness and wobbly leg whenever patient tried to get up cannot stay up for long (almost fell getting off the truck), cannot stand up, extreme tenderness in the arm (injection site), felt extremely lethargic, and slight and mild shortness of breath. This report was non-serious.
Hot and flushed feeling the first night, then chills by morning.  2nd and 3rd night definitely had fever of around 100.5 and sweated out  the fever in the middle of night.  Very tired the first day afterwards and still not feeling well the second full day afterwards.  Arm near injection site is inflamed and sore, but getting better.
Extreme pain in left shoulder, inability to move left shoulder/arm, swelling in arm, extreme fatigue, extreme muscle pain in upper back.
injection site was red and had a lump; injection site was red and had a lump; This spontaneous case was reported by a patient and describes the occurrence of INJECTION SITE MASS (injection site was red and had a lump) and INJECTION SITE ERYTHEMA (injection site was red and had a lump) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-May-2021, the patient experienced INJECTION SITE MASS (injection site was red and had a lump) and INJECTION SITE ERYTHEMA (injection site was red and had a lump). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Injection site lump and Injection site redness, at a dose of 1 dosage form. At the time of the report, INJECTION SITE MASS (injection site was red and had a lump) and INJECTION SITE ERYTHEMA (injection site was red and had a lump) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Pt recvd MMR on 18JUN90; 10 days post vax pt devel fever, petechial rash & swollen lymph nodes neccessitating admission to Hosp; Sepsis workup was neg & platelet count was normal; Pt d/c & recovered p/3 days;
On April 8, I began to feel extremely tired and unwell. During that night, I woke up dizzy and feeling sick to my stomach. I experienced extreme dizziness, jaw pain, headache, light sensitivity, vomiting (once), pain in my lower abdomen, several bowel movements, loss of appetite, and I slept during the day and night. It was very difficult to stand upright or walk. I began to feel better April 11 and was able to eat and walk. I still have a bit of dizziness and nauseousness, but I am able to eat, walk, and do daily activities.
2.5 x 2.5 redness and swelling with warmth to (L) deltoid injection site.
pt recvd vax; post vax encephalitis; persistent fever (reached 103.6 9oct94) ; h/a, n, & achy joints; still has trouble concentrating;
Information was received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received concerning the patient's past medical history, concurrent conditions, or concomitant medication. On or about 15-AUG-2011, the patient was inoculated at a pharmacy with ZOSTAVAX (lot number, dosage, and route of administration not provided), as recommended for routine adult health maintenance and for the prevention of shingles. The ZOSTAVAX vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about 24-JUN-2015, the patient was treated by a Nurse Practitioner for the onset of a severe vesicular rash accompanied by weakened immune symptoms, which was diagnosed as herpes zoster, or shingles. The patient was prescribed  hydrocodone bitartrate and acetaminophen (NORCO) and gabapentin for management of her painful symptoms. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
I had flu-like symptoms after the first shot; Achiness; chills; sore muscles; difficulty breathing; This is a spontaneous report from a contactable consumer or other non hcp. A 65-years-old male patient received the first dose of Bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Batch/Lot Number: EN6203), dose 1 via an unspecified route of administration, administered in Arm Left on 26Feb2021 at 12:15pm (at the age of 65-years-old) as a single dose for covid-19 immunisation. Medical history included hypertension from an unknown date and unknown if ongoing, on an unspecified date in Mar2020 patient had affected with covid-19 and unknown if ongoing. Since the vaccination, the patient had not been tested for covid-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took Albuterol Sulfate which was prescribed in last year. The patient reported that on 20Mar2021 at 01:00 AM he had flu-like symptoms after the first shot, the patient had achiness, chills, sore muscles and difficulty breathing and those subsided within 24 hours. The patient received second dose of vaccine on 19Mar2021 at 12:15 PM (Batch/Lot: EN6207). The patient was recovering from the events.  No follow-up attempts are needed. No Further information is expected. .
pt recv vax;fainted;felt dizzy first;when awake, responsive & pale;BP 88/42;rested, cool compress applied to forehead;now feels better;
Pfizer- BioNTech Covid-19 vaccine treatment under Emergency Use Authorization(EUA): While drawing up vaccine, debris in a syringe was noticed. The needle/syringe was immediately from the vaccine vial and the safety cap was placed on the syringe. The vaccine vial and other doses that had been obtained that vial were inspected, all solution was clear, colorless, with no particles or debris in the vial or other syringes. Syring: 1ml Luek-Lok syringe. LOT#: 0196715 (Exp 2025-06-30) Needle: 23G x 1.5 inches LOT#: 2009055 (Exp: 2025-09-28)
Pt chilled, ached dyspnea, poss sz, limp, cyanotic, t103.5;
Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. In 2013, the patient was vaccinated with ZOSTAVAX, (lot# and route unknown) for routine adult health maintenance for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster, also known as shingles and other complications. On or about 24-DEC-2015, the patient was treated at a medical facility for a blistering vesicular outbreak that was diagnosed as severe herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX, for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering and other damages. Additional information has been requested.
29JUL92 recvd vax & 24 hr later noted to have redness & induration of inject site w/local irritation; next morning awoke to a generalized rash on upper/lower extremities w/itching;
Day 1  none noted Day 2  extreme overall body aches, headache, fever (101.2) chills. Took Tylenol  one time -30 hrs. after injection Day3   fever and aches began subsiding  *now noted itchy, red, hive-like rash, warm to touch- around upper and inner arm around  injection site as well as sore and swollen lymph node in armpit of same arm. Took Tylenol  2 times  Ice to arm Day 4  fever, aches, headache subsided.  Red rash on arm larger, red, itchy, warm and node still sore (no fever) Ice to arm and took 10 mg Cetirizine
I63.9 ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 4/12/2023 ACUTE STROKE OF BASAL GANGLIA, UNSPECIFIED TYPE AND ARTERY I63.9 ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 4/12/2023 ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY
This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732), via an unspecified route of administration in the left arm on 31Mar2021 at 11:15 (at the age of 51-years-old), as a single dose for COVID-19 immunisation. Medical history included arthritis tail bone, obesity and allergy to cow's milk. Concomitant medications included triamterene (MANUFACTURER UNKNOWN) for an unspecified indication from an unknown date. The patient previously took ibuprofen (MANUFACTURER UNKNOWN) and aspirin (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccination. On 31Mar2021 at 12:00 the patient experienced diarrhea, intermittent bouts about every 30 to 60 minutes apart. First bout roughly 45 minutes after the shot. The events did not result in doctor or other healthcare professional office/clinic visit, and the emergency room/department or urgent care. It was unknown if the patient was treated for the event. The clinical outcome of the diarrhea was unknown.  No follow-up attempts are needed. No further information is expected.
Narrative:  76yr patient presented to ED on 9/27 concerns for SOB, fever, chills, cough, tachycardic, and hypotensive. COVID tested positive with elevated Trop. Differential diagnosis: likely type 2 NSTEMI in setting of COVID; admitted to the ICU for further management. Was not requiring O2 until late evening of 9/28 (4L via oxymask) then next day able to wean to 2L then off. COVID Therapeutics: dexamethasone 6mg po daily (x 2 doses) Inpatient stay: 2 days PMH: psoriatic arthritis, myelodysplastic syndrome, AS, and gerd along with taking immunosuppressant medications (prednisone 7.5mg daily. COVID vaccinations (Moderna x 2 including 3rd dose; 1/20/21, 2/17/2021, and 9/21/2021)
Migratory pain that started in my low back a few days post second COVID vaccine which spontaneously resolved within a couple days.  Spontaneous Right knee pain and swelling developed a couple days after that which makes normal ambulation difficult.  The pain responds to., but isn't completely resolved by, 400 mg Ibuprofen but is unaffected by 1000mg Tylenol.   I have never had a knee injury nor did anything to cause the acute pain.  I am in good shape, at a healthy weight ( I am 5 ' 3" and weigh 117 pounds ) and eat a well balanced and healthy diet.  I am now unable to enjoy my usual activities and cannot complete tasks around my home without pain.
Myalgia, Fever, Rash, ARM SORE, FATIGUE, RASH/HIVES/SWELLING AT INJECTION SITE Narrative:    Other Relevant History:
This spontaneous case, initially received on 29-Nov-2016, was reported by a health professional and concerns a female patient. Weight: not provided; Height: not provided. Concomitant medication: not reported. Administration of company suspect drug(s): On an unknown date, the patient received AFLURIA. Dose regimen: 0.5 ml, Route of administration: Not reported. Batch number: 12849211A. No additional suspect drugs. Adverse reactions/events and outcomes: On an unknown date, the vial leaked onto RN (registered nurse) finger when withdrawing doses (outcome: not reported, special circumstances: occupational exposure to product), started leaking after 3rd puncture (outcome: not reported, special circumstances: medication error). Reporter comments: The healthcare professional classified the report as occupational exposure and quality defect.
pt rcvd vax; pt devel flu-like symptoms of fever, achiness & malaise; pt devel also abdominal pain; exam revealed an anal polyp & a II/VI early systolic murmur; lab eval HBs neg; pt tx w/ APAP & diphenhydramine HC1 (benadryl) prior to vax;
Sudden suicide one week after the vaccine. Patient was a perfectly happy child. After the vaccine, he became much more tired and achy and lost interest in doing his sports. One week later, without any warning, he hung himself.
Client received Yellow fever vaccine on 10/17/02 and complained of left deltoid having large amount of redness, warm to touch, itchy, rash like appearance that developed at PM of 10/17/02. Also had dizziness and pounding to ears for 2 days. Afebrile and denies nausea and vomiting. Client informed nurse of incident on 11/7/02.
At 1700,  A family arrived  at clinic to receive vaccines. There were 4 people in the vehicle wanting to be vaccinated two adults and two children. The children were a 2 y/o Female and a 4 y/o female . Their parent requested that they receive their third dose  of infant pfizer. Rather than being given the infant pfizer they recieved pediactric  pfizer around 1712 . Following the event. The family was observed in observation for 15 minutes and no adverse reactions noted or abnormalities. The family left following this. The mother of the patient's was contacted, informed of the med error, and advised to notify the pediatrician to follow up.  At the time of this phone call (1820), the mother stated that no adverse reaction symptoms were noted.
24 hours after the vaccine was administered, my daughter, the patient, broke out in a burning rash in her left armpit - same arm as vaccine.  We thought it was "Covid Arm" and would resolve in a couple of day, however, the rash felt and looked worse.  We went to a walk in clinic yesterday 8/17/21 and she was diagnosed with SHINGLES, not "Covid arm".  The Covid vaccine triggered an immune response which resulted in a painful bout of Shingles.  Now she on MethylPrednisolone and a topical Acyclovir/Hydrocortisone ointment.
Mom called next day to report child itchy with red bumps all over (child has similar reaction to immunizations as infant). Per doctor, mom was instructed to give Benadryl as long as no anaphylactic reaction noted (explained anaphylactic). Mom also asked about giving Motrin; told she could.
rash, vomiting, fever 103, onset 15SEP92 taken to hosp ER on 16SEP92; dx Roseola; sx subsiding on 18SEP92;